Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and coronary heart disease risk in familial hypercholesterolemia

Atherosclerosis

Volumn 203, Issue 2, 2009, Pages 472-478

  van der Net, Jeroen B ^a   Versmissen, Jorie ^a   Oosterveer, Daniëlla M ^a   Defesche, Joep C ^b   Yazdanpanah, Mojgan ^a   Aouizerat, Bradley E ^c   Steyerberg, Ewout W ^a   Malloy, Mary J ^c,d   Pullinger, Clive R ^c   Kane, John P ^c,d   Kastelein, John J P ^b   Sijbrands, Eric J G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ALOX5AP; Coronary heart disease; Familial hypercholesterolemia; FLAP; Genetics; Lipoxygenase

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; LEUKOTRIENE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTERY WALL; ARTICLE; BIRTH; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CIGARETTE SMOKING; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE SEVERITY; DNA MODIFICATION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HEART INFARCTION; HUMAN; ICELAND; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SEX DIFFERENCE; UNITED KINGDOM;

ADULT; CARRIER PROTEINS; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY DISEASE; FEMALE; GENETIC VARIATION; HAPLOTYPES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INFLAMMATION; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK;

EID: 62649140865     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.07.025     Document Type: Article

References (30)

1. Goldstein J.L., Hobbs H.H., and Brown M.S. Familial hypercholesterolemia. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The metabolic and molecular bases of inherited disease. eighth ed. (2001), McGraw-Hill, New York 2863-2913
2. van Aalst-Cohen E.S., Jansen A.C., de Jongh S., de Sauvage Nolting P.R., and Kastelein J.J. Clinical, diagnostic, and therapeutic aspects of familial hypercholesterolemia. Semin Vasc Med 4 (2004) 31-41
3. Sijbrands E.J., Westendorp R.G., Defesche J.C., et al. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ 322 (2001) 1019-1023
4. Umans-Eckenhausen M.A., Sijbrands E.J., Kastelein J.J., and Defesche J.C. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation 106 (2002) 3031-3036
5. Jansen A.C., van Aalst-Cohen E.S., Tanck M.W., et al. Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 25 (2005) 1475-1481
6. Sijbrands E.J., Westendorp R.G., Paola L.M., et al. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. Atherosclerosis 149 (2000) 421-425
7. Dixon R.A., Diehl R.E., Opas E., et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343 (1990) 282-284
8. Zhao L., and Funk C.D. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc Med 14 (2004) 191-195
9. Holven K.B., Myhre A.M., Aukrust P., et al. Patients with familial hypercholesterolaemia show enhanced spontaneous chemokine release from peripheral blood mononuclear cells ex vivo. Dependency of xanthomas/xanthelasms, smoking and gender. Eur Heart J 24 (2003) 1756-1762
10. Stokes K.Y., Cooper D., Tailor A., and Granger D.N. Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide. Free Radic Biol Med 33 (2002) 1026-1036
11. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
12. Helgadottir A., Manolescu A., Thorleifsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 (2004) 233-239
13. Kajimoto K., Shioji K., Ishida C., et al. Validation of the association between the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a Japanese population. Circ J 69 (2005) 1029-1034
14. Girelli D., Martinelli N., Trabetti E., et al. ALOX5AP gene variants and risk of coronary artery disease: an angiography-based study. Eur J Hum Genet 15 (2007) 959-966
15. Linsel-Nitschke P., Gotz A., Medack A., et al. Genetic variation in the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) is associated with myocardial infarction in the German population. Clin Sci (Lond) (2008)
16. Jansen A.C., van Aalst-Cohen E.S., Tanck M.W., et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 256 (2004) 482-490
17. Jansen A.C., van Aalst-Cohen E.S., Hutten B.A., et al. Guidelines were developed for data collection from medical records for use in retrospective analyses. J Clin Epidemiol 58 (2005) 269-274
18. Ihaka R., and Gentleman R.R. A language for data analysis and graphics. J Comput Graph Stat 5 (1996) 299-314
19. Haldane J.B.S. An exact test for randomness of mating. J Genet 52 (1954) 631-635
20. van der Net J.B., Janssens A.C., Eijkemans M.J., et al. Cox proportional hazards models have more statistical power than logistic regression models in cross-sectional genetic association studies. Eur J Hum Genet (2008) [Epub ahead of print]
21. Kramer A., Jansen A.C., van Aalst-Cohen E.S., et al. Relative risk for cardiovascular atherosclerotic events after smoking cessation: 6-9 years excess risk in individuals with familial hypercholesterolemia. BMC Public Health 6 (2006) 262
22. Stephens M., Smith N.J., and Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68 (2001) 978-989
23. Zee R.Y., Cheng S., Hegener H.H., Erlich H.A., and Ridker P.M. Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case-control approach. Stroke 37 (2006) 2007-2011
24. Koch W., Hoppmann P., Mueller J.C., Schomig A., and Kastrati A. No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population. Genet Med 9 (2007) 123-129
25. Samuelsson B., Dahlen S.E., Lindgren J.A., Rouzer C.A., and Serhan C.N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237 (1987) 1171-1176
26. Hakonarson H., Thorvaldsson S., Helgadottir A., et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 293 (2005) 2245-2256
27. Abuzeid A.M., Hawe E., Humphries S.E., and Talmud P.J. Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis 168 (2003) 283-288
28. Ameziane N., Beillat T., Verpillat P., et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 23 (2003) e61-e64
29. Bisoendial R.J., Kastelein J.J., Peters S.L., et al. Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J Lipid Res 48 (2007) 952-960
30. Fair A., and Pritchard Jr. K.A. Oxidized low density lipoprotein increases U937 cell 5-lipoxygenase activity: induction of 5-lipoxygenase activating protein. Biochem Biophys Res Commun 201 (1994) 1014-1020